Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2020-10-08 Sale |
2020-10-13 7:41 pm |
Black Diamond Therapeutics Inc. | BDTX | Versant Venture Capital VI L.P. Versant Voyageurs I Parallel L.P. Versant Voyageurs I L.P. Versant Vantage I L.P. 10% Owner |
22,625 | $33.5 | $757,924 | 8,854,094 (Indirect Direct) |
View |
| 2020-10-08 Sale |
2020-10-09 4:12 pm |
Black Diamond Therapeutics Inc. | BDTX | Leggett Thomas Chief Financial Officer |
3,000 | $33.53 | $100,576 | 227,171 (Direct) |
View |
| 2020-10-06 Sale |
2020-10-08 7:14 pm |
Black Diamond Therapeutics Inc. | BDTX | Bolzon Bradley J PhD Director 10% Owner |
45,926 | $33.44 | $1,535,732 | 311,881 (Indirect Direct) |
View |
| 2020-10-06 Sale |
2020-10-08 7:14 pm |
Black Diamond Therapeutics Inc. | BDTX | Versant Venture Capital VI L.P. Versant Voyageurs I Parallel L.P. Versant Voyageurs I L.P. Versant Vantage I L.P. 10% Owner |
45,926 | $33.44 | $1,535,732 | 6,056,892 (Indirect Direct) |
View |
| 2020-10-05 Sale |
2020-10-07 4:27 pm |
Black Diamond Therapeutics Inc. | BDTX | Roberts Christopher D. Chief Scientific Officer |
2,500 | $31.28 | $78,188 | 189,309 (Direct) |
View |
| 2020-10-01 Sale |
2020-10-02 5:07 pm |
Black Diamond Therapeutics Inc. | BDTX | Epstein David M. See Remarks |
12,000 | $30.33 | $363,962 | 1,227,685 (Indirect Direct) |
View |
| 2020-09-30 Purchase |
2020-10-01 4:06 pm |
Black Diamond Therapeutics Inc. | BDTX | INGRAM ROBERT ALEXANDER Director |
5,000 | $30.46 | $152,285 | 5,000 (Direct) |
View |
| 2020-09-14 Sale |
2020-09-16 6:11 pm |
Black Diamond Therapeutics Inc. | BDTX | Hatzis-Schoch Brent See Remarks |
4,078 | $31.04 | $126,583 | 201,498 (Direct) |
View |
| 2020-09-14 Sale |
2020-09-16 6:09 pm |
Black Diamond Therapeutics Inc. | BDTX | Leggett Thomas Chief Financial Officer |
3,000 | $31 | $93,000 | 230,171 (Direct) |
View |
| 2020-09-03 Sale |
2020-09-04 5:27 pm |
Black Diamond Therapeutics Inc. | BDTX | Roberts Christopher D. Chief Scientific Officer |
2,500 | $29.59 | $73,987 | 191,809 (Direct) |
View |
| 2020-08-10 Sale |
2020-08-12 7:57 pm |
Black Diamond Therapeutics Inc. | BDTX | Versant Venture Capital VI L.P. Versant Voyageurs I Parallel L.P. Versant Voyageurs I L.P. Versant Vantage I L.P. 10% Owner |
13,792 | $33.06 | $455,989 | 10,541,469 (Indirect Direct) |
View |
| 2020-08-10 Sale |
2020-08-12 7:46 pm |
Black Diamond Therapeutics Inc. | BDTX | Bolzon Bradley J PhD Director 10% Owner |
13,792 | $33.06 | $455,989 | 9,417,182 (Indirect Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2020-10-08 Exercise |
2020-10-09 4:12 pm |
N/A 2029-09-08 |
Black Diamond Therapeutics Inc. | BDTX | Leggett Thomas Chief Financial Officer |
3,000 | $0 | 227,171 (Direct) |
View |
| 2020-10-08 Exercise |
2020-10-09 4:12 pm |
N/A N/A |
Black Diamond Therapeutics Inc. | BDTX | Leggett Thomas Chief Financial Officer |
3,000 | $10.86 | 227,171 (Direct) |
View |
| 2020-10-07 Other |
2020-10-08 7:14 pm |
N/A N/A |
Black Diamond Therapeutics Inc. | BDTX | Bolzon Bradley J PhD Director 10% Owner |
300,522 | $0 | 311,881 (Indirect) |
View |
| 2020-10-07 Other |
2020-10-08 7:14 pm |
N/A N/A |
Black Diamond Therapeutics Inc. | BDTX | Versant Venture Capital VI L.P. Versant Voyageurs I Parallel L.P. Versant Voyageurs I L.P. Versant Vantage I L.P. 10% Owner |
299,051 | $0 | 6,056,892 (Indirect) |
View |
| 2020-10-05 Exercise |
2020-10-07 4:27 pm |
N/A 2029-09-08 |
Black Diamond Therapeutics Inc. | BDTX | Roberts Christopher D. Chief Scientific Officer |
2,500 | $0 | 189,309 (Direct) |
View |
| 2020-10-05 Exercise |
2020-10-07 4:27 pm |
N/A N/A |
Black Diamond Therapeutics Inc. | BDTX | Roberts Christopher D. Chief Scientific Officer |
2,500 | $10.86 | 189,309 (Direct) |
View |
| 2020-10-01 Exercise |
2020-10-02 5:07 pm |
N/A 2029-08-13 |
Black Diamond Therapeutics Inc. | BDTX | Epstein David M. See Remarks |
3,000 | $0 | 1,227,685 (Direct) |
View |
| 2020-10-01 Exercise |
2020-10-02 5:07 pm |
N/A N/A |
Black Diamond Therapeutics Inc. | BDTX | Epstein David M. See Remarks |
3,000 | $6.42 | 1,227,685 (Direct) |
View |
| 2020-09-25 Option Award |
2020-09-29 08:21 am |
N/A 2030-09-25 |
Black Diamond Therapeutics Inc. | BDTX | INGRAM ROBERT ALEXANDER Director |
29,842 | $0 | 29,842 (Direct) |
View |
| 2020-09-17 Other |
2020-09-21 7:51 pm |
N/A N/A |
Black Diamond Therapeutics Inc. | BDTX | Bolzon Bradley J PhD Director 10% Owner |
758,523 | $0 | 784,495 (Indirect) |
View |
| 2020-09-17 Other |
2020-09-21 7:28 pm |
N/A N/A |
Black Diamond Therapeutics Inc. | BDTX | Versant Venture Capital VI L.P. Versant Voyageurs I Parallel L.P. Versant Voyageurs I L.P. Versant Vantage I L.P. 10% Owner |
754,743 | $0 | 6,569,238 (Direct) |
View |
| 2020-09-14 Exercise |
2020-09-16 6:11 pm |
N/A 2029-06-11 |
Black Diamond Therapeutics Inc. | BDTX | Hatzis-Schoch Brent See Remarks |
4,078 | $0 | 201,498 (Direct) |
View |
| 2020-09-14 Exercise |
2020-09-16 6:11 pm |
N/A N/A |
Black Diamond Therapeutics Inc. | BDTX | Hatzis-Schoch Brent See Remarks |
4,078 | $3.2 | 201,498 (Direct) |
View |
| 2020-09-14 Exercise |
2020-09-16 6:09 pm |
N/A 2029-09-08 |
Black Diamond Therapeutics Inc. | BDTX | Leggett Thomas Chief Financial Officer |
3,000 | $0 | 230,171 (Direct) |
View |
| 2020-09-14 Exercise |
2020-09-16 6:09 pm |
N/A N/A |
Black Diamond Therapeutics Inc. | BDTX | Leggett Thomas Chief Financial Officer |
3,000 | $10.86 | 230,171 (Direct) |
View |
| 2020-09-08 Option Award |
2020-09-10 4:56 pm |
N/A 2030-09-08 |
Black Diamond Therapeutics Inc. | BDTX | HUMPHREY RACHEL Chief Medical Officer |
160,000 | $0 | 160,000 (Direct) |
View |
| 2020-09-03 Exercise |
2020-09-04 5:27 pm |
N/A 2029-09-08 |
Black Diamond Therapeutics Inc. | BDTX | Roberts Christopher D. Chief Scientific Officer |
2,500 | $0 | 191,809 (Direct) |
View |
| 2020-09-03 Exercise |
2020-09-04 5:27 pm |
N/A N/A |
Black Diamond Therapeutics Inc. | BDTX | Roberts Christopher D. Chief Scientific Officer |
2,500 | $10.86 | 191,809 (Direct) |
View |
| 2020-08-18 Other |
2020-08-20 6:13 pm |
N/A N/A |
Black Diamond Therapeutics Inc. | BDTX | Bolzon Bradley J PhD Director 10% Owner |
312,894 | $0 | 4,073,236 (Indirect) |
View |
| 2020-08-18 Other |
2020-08-20 6:13 pm |
N/A N/A |
Black Diamond Therapeutics Inc. | BDTX | Versant Venture Capital VI L.P. Versant Voyageurs I Parallel L.P. Versant Voyageurs I L.P. Versant Vantage I L.P. 10% Owner |
311,176 | $0 | 10,263,821 (Direct) |
View |
| 2020-08-12 Other |
2020-08-14 5:55 pm |
N/A N/A |
Black Diamond Therapeutics Inc. | BDTX | Versant Venture Capital VI L.P. Versant Voyageurs I Parallel L.P. Versant Voyageurs I L.P. Versant Vantage I L.P. 10% Owner |
311,176 | $0 | 10,563,821 (Direct) |
View |
| 2020-08-12 Other |
2020-08-14 5:54 pm |
N/A N/A |
Black Diamond Therapeutics Inc. | BDTX | Bolzon Bradley J PhD Director 10% Owner |
312,894 | $0 | 4,071,518 (Direct) |
View |
| 2020-07-27 Other |
2020-07-29 9:56 pm |
N/A N/A |
Black Diamond Therapeutics Inc. | BDTX | Versant Venture Capital VI L.P. Versant Voyageurs I Parallel L.P. Versant Voyageurs I L.P. Versant Vantage I L.P. 10% Owner |
339,843 | $0 | 7,151,621 (Indirect) |
View |
| 2020-07-27 Other |
2020-07-29 9:54 pm |
N/A N/A |
Black Diamond Therapeutics Inc. | BDTX | Bolzon Bradley J PhD Director 10% Owner |
341,334 | $0 | 7,154,603 (Indirect) |
View |